September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents

Oncologist

Volumn 13, Issue SUPPL. 3, 2008, Pages 33-36

  Aapro, Matti S ^a,c   Link, Hartmut ^b  

^a Multidisciplinary Oncology Institute   (Switzerland)

^b Westpfalz Klinikum GmbH   (Germany)

^c CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

2007 EORTC guidelines; Anemia; Erythropoiesis stimulating agents

Indexed keywords

IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; ARTICLE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; NEOPLASM;

ANEMIA; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HEMOGLOBINS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 49249083689     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.13-S3-33     Document Type: Review

References (27)

1. Ludwig H, Van Belle S, Barrett-Lee Pet al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
2. Bokemeyer C, Aapro MS. Courdi A et al.; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-270.
3. Aapro M, Abraham I, Bokemeyer C et al. The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: A global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. Support Care Cancer 2008;16:193-200.
4. Harper P. Littlewood T. Anaemia of cancer: Impact on patient fatigue and long-term outcome. Oncology 2005;69(suppl 2):2-7.
5. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001;91:2214-2221.
6. Tesarova P, Kvasnicka J. [Treatment of anemia in patients with tumors.] Cas Lek Cesk 1995;134:647-650. Czech.
7. DeRienzo DP, Saleem A. Anaemia of chronic disease: A review of patho-genesis. Tex Med 1990;86:80-83.
8. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25(suppl 7):2-6.
9. Brittenham GM, Klein HG, Kushner JP et al. Preserving the national blood supply. Hematology Am Soc Hematol Educ Program 2001;422-432.
10. Wilson J, Yao GL, Raftery J et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-202, iii-iv.
11. Vamvakas EC, Taswell HF. Long-term survival after blood transfusion. Transfusion 1994;34:471-477.
12. Bennett-Guerrero E, Veldman TH, Doctor A et al. Evolution of adverse changes in stored R BCs. Proc Natl Acad Sci U S A 2007;104:17063-17068.
13. Leal-Noval SR, Jara-Lopez I. Garcia-Garmendia J L et al. Influence of erythrocyte concentrate storage time on postsurgical morbidity in cardiac surgery patients. Anesthesiology 2003;98:815-822.
14. Purdy FR, Tweeddale MG, Merrick PM. Association of mortality withage of blood transfused in septic ICU patients. Can J Anaesth 1997;44:1256-1261.
15. Zallen G. Offner PJ, Moore EE et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg 1999;178:570-572.
16. Vincent JL, Baron JF. Reinhart K et al. Anemia and blood transfusion in critically ill patients. JAMA 2002:288:1499-1507.
17. Kuduvalli M. Oo AY, Newall N et al. Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. Eur J Cardiothorac Surg 2005;27:592-598.
18. Koch CG, Li L, Duncan Al et al. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg 2006;81:1650-1657.
19. Rao S V, Jollis JG, Harrington R A et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-1562.
20. Hill SR, Carless PA, Henry DA et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2002;(2):CD002042.
21. Witzig TE. Silberstein PT. Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
22. Demetri GD. Kris M, Wade J et al. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Pro-crit Study Group. J Clin Oncol 1998;16:3412-3425.
23. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
24. Gabrilove JL, Cleeland CS. Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
25. Nortier J WR. Zagari M, Chen Y et al. Marginal analysis to identify optimal hemoglobin levels to maximise quality of life improvement in anemic cancer patients receiving epoetin alfa. Ann Oncol 2000:11 (suppl 4): 145-146.
26. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
27. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-2216.